Initiatives

The consortium’s efforts are to advance the Neurapheresis™ therapy into human clinical research, and ultimately into the clinic for multiple indications. The Neurapheresis therapy is built on a proprietary technology platform developed by Minnetronix that is designed to prevent secondary injury and enhance healing by removing disease causing agents from the cerebrospinal fluid. Current areas of research include the following unmet clinical challenges.

  • Current initiatives

    • Aneurysmal subarachnoid hemorrhage (aSAH)

    • Cryptococcal Meningitis

    • Leptomeningeal Carcinomatosis

The NRC continues to identify new indications to explore and develop for potential treatment with the Neurapheresis therapy. We invite potential collaborators to contact us for research opportunities in all current and potential indications, including:

  • Gram-Negative Bacterial Meningitis

  • Human Immunodeficiency Virus (HIV)

  • Multiple sclerosis

  • Guillain-Barre Syndrome (GBS)

  • Herpes Encephalitis

  • Amyotrophic Lateral Sclerosis (ALS)

Contact NRC for more information about our programs or participation inquiries, contact us.
CAUTION – Investigational Device, limited by Federal Law to Investigational Use.
Minnetronix is a registered trademark, and Neurapheresis is a trademark of Minnetronix, Inc.
©Minnetronix, Inc. All rights reserved.